Deep brain stimulation (DBS) of the subthalamic nucleus (STN) has become an accepted treatment for motor symptoms in a subset of Parkinson's disease (PD) patients. The mechanisms why DBS is effective are incompletely understood, but previous studies show that DBS targeted in brain structures other than the STN may modify the microvasculature. However, this has not been studied in PD subjects who have received STN-DBS. Here we investigated the extent and nature of microvascular changes in post-mortem STN samples from STN-DBS PD patients, compared to aged controls and PD patients who had not been treated with STN-DBS. We used immunohistochemical and immunofluorescent methods to assess serial STN-containing brain sections from PD and STN-DBS PD cases, compared to similar age controls using specific antibodies to detect capillaries, an adherens junction and tight junction-associated proteins as well as activated microglia. Cellular features in stained sections were quantified by confocal fluorescence microscopy and stereological methods in conjunction with in vitro imaging tools. We found significant upregulation of microvessel endothelial cell thickness, length and density but lowered activated microglia density and striking upregulation of all analysed adherens junction and tight junction-associated proteins in STN-DBS PD patients compared to non-DBS PD patients and controls. Moreover, in STN-DBS PD samples, expression of an angiogenic factor, vascular endothelial growth factor (VEGF), was significantly upregulated compared to the other groups. Our findings suggest that overexpressed VEGF and downregulation of inflammatory processes may be critical mechanisms underlying the DBS-induced microvascular changes. © 2014 Elsevier Inc. All rights reserved.
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Introduction
In the brains of Parkinson's disease (PD) patients, the degeneration of neurons in the substantia nigra pars compacta (SNpc) results in loss of dopamine (DA) content in the caudate nucleus and putamen, triggering downstream changes in the activity of the basal ganglia output pathways. These changes include increased activity of glutamatergic pathways originating from the subthalamic nucleus (STN) segment of the basal ganglia's indirect pathway that projects to the internal segment of the globus pallidus (GPi) and substantia nigra reticulata (SNr), resulting in PD motor symptoms (Bergman et al., 1990; Smith et al., 1998) . Moreover, a hyperactive STN-SNpc pathway ensues, potentially reinforcing neurodegeneration of the SNpc dopaminergic neurons via glutamate-mediated excitotoxicity (Miller and DeLong, 1987; Bergman et al., 1994) .
Such insights resulted in the development of deep brain stimulation (DBS) of the STN (STN-DBS), with studies showing a marked reduction in motor fluctuations and the disappearance of drug-induced dyskinesias in STN-DBS PD patients (Limousin et al., 1998) . These patients also exhibited improved axial functions (Ngoga et al., 2014) and slower PD progression (Tagliati et al., 2010) . This is in accordance with other studies (e.g. Temel et al., 2006) , demonstrating that STN-DBS protected nigral neuronal loss in the 6-hydroxydopamine (6-OHDA) rat model of PD. Similarly, Wallace et al. (2007) observed that STN-DBS applied both before and after 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) administration to primates prevented further loss of SNpc dopaminergic neurons compared to sham-surgery controls.
Although STN-DBS as a therapeutic option has existed for 25 years, the mechanisms responsible for symptom improvement remain largely
